Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up

耐火材料(行星科学) 医学 内科学 二线治疗 核医学 胃肠病学 肿瘤科 物理 化疗 天体生物学
作者
Jeremy S. Abramson,Manali Kamdar,Fei Fei Liu,Alessandro Crotta,Alessandro Previtali,S. Klijn,Pearl Wang,Yixie Zhang,Ashley Bonner,Matthew A. Lunning
出处
期刊:Blood [Elsevier BV]
卷期号:144 (Supplement 1): 3130-3130
标识
DOI:10.1182/blood-2024-200937
摘要

Background: Two CAR T cell therapies, liso-cel and axi-cel, demonstrated superior efficacy over salvage chemotherapy and autologous transplant as 2L therapy in transplant-intended pts with high-risk R/R LBCL, yet no head-to-head comparisons have been performed. A previous MAIC in the 2L setting with a median follow-up of 17.5 mo for liso-cel and 24.9 mo for axi-cel showed comparable efficacy and more favorable safety outcomes for liso-cel with lower rates of all-grade and grade ≥ 3 cytokine release syndrome (CRS) and neurological events (NEs) (Abramson JS, et al. Blood 2022). Here, we present updated results with long-term follow-up for liso-cel and axi-cel. Methods: MAICs were used to estimate population-adjusted relative treatment effects associated with liso-cel for event-free survival (EFS), PFS, ORR, and CR rate (TRANSFORM; NCT03575351; N = 184; data cutoff date: October 2023) vs axi-cel (ZUMA-7; NCT03391466; N = 359; data cutoff date: January 2023) and safety (TRANSFORM, n = 183; ZUMA-7, n = 338). Pts were excluded from the TRANSFORM data set if they did not meet ZUMA-7 eligibility criteria (ie, matching). Individual pt data (IPD) for pts remaining in the TRANSFORM data set were weighted using a method-of-moments propensity score model to match the marginal distribution (ie, mean, variance) of clinical factors among pts from ZUMA-7 (ie, adjustment). Baseline characteristics and outcome measures were revised to align with those defined in ZUMA-7. Efficacy comparisons were anchored through the common comparator, standard of care (SOC; with similar protocol-defined salvage chemotherapy regimens in both trials, followed by high-dose chemotherapy and autologous transplant in responders). Hazard ratios (HRs) were used to compare time-to-event outcomes (EFS, PFS), and odds ratios were used to compare binary outcomes (ORR, CR rate, safety). Selection and rank ordering of the treatment effect modifiers were guided by analysis of the TRANSFORM IPD and clinical experts. Factors to match (ie, pts from TRANSFORM were removed) and adjust (ie, pts from TRANSFORM were reweighted) for efficacy and safety comparisons were reported previously (Abramson JS, et al. Blood 2022). Safety comparisons were unanchored due to the absence of CAR T cell-associated toxicities in the SOC arms. Bridging chemotherapy was allowed in TRANSFORM but not in ZUMA-7; it was not possible to adjust for this factor given sample size constraints. Results: Median study follow-up time was 33.9 mo for liso-cel and 47.2 mo for axi-cel. Efficacy outcomes were comparable between therapies in the unmatched/unadjusted comparison. For liso-cel vs axi-cel, respectively, median (95% CI) EFS was 29.5 mo (9.5‒not reached [NR]) vs 8.3 mo (4.5‒15.8) with HR (95% CI) of 0.94 (0.60‒1.46), and median (95% CI) PFS was 29.5 mo (10.3‒NR) vs 14.7 mo (5.4‒43.5) with HR of 0.90 (95% CI, 0.56‒1.47). Median ORR was 87% vs 83% with odds ratio (95% CI) of 1.41 (0.58‒3.40), and CR rate was 74% vs 65% with odds ratio (95% CI) of 0.95 (0.44‒2.03). After matching with ZUMA-7 for pt eligibility, the TRANSFORM sample size was 158; matching and adjusting for the selected effect modifiers resulted in an effective sample size of 80 for the primary efficacy scenario comparisons (sample size for ZUMA-7 and median efficacy values for axi-cel were unchanged). After matching and adjustment, efficacy outcomes remained comparable between therapies. Median (95% CI) EFS for liso-cel was NR (6.21‒NR) with HR (95% CI) of 0.75 (0.43‒1.33), and median (95% CI) PFS was NR (9.4-NR) with HR (95% CI) of 0.68 (0.37‒1.23). ORR was 85% with odds ratio (95% CI) of 1.63 (0.60‒4.44), and CR rate was 68% with odds ratio (95% CI) of 0.94 (0.40‒2.22). For safety, MAIC results demonstrated lower odds ratios (95% CI) of grade ≥ 3 serious treatment-emergent adverse events (TEAEs; 0.49 [0.27‒0.90]), CRS (any grade, 0.09 [0.04‒0.18]; grade ≥ 3, 0.09 [0.01‒0.75]), and NEs (any grade, 0.08 [0.03‒0.18]; grade ≥ 3, 0.21 [0.06‒0.68]) for liso-cel vs axi-cel. Conclusions: Results from this updated MAIC of liso-cel and axi-cel for the 2L treatment of R/R LBCL showed comparable efficacy, with more favorable safety outcomes for liso-cel. Liso-cel demonstrated a better safety profile with lower rates of grade ≥ 3 serious TEAEs and lower rates of all-grade and grade ≥ 3 CRS and NEs compared with axi-cel.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
nczpf2010完成签到,获得积分10
刚刚
不知道叫啥完成签到 ,获得积分10
1秒前
cssc完成签到,获得积分10
2秒前
华仔的应助被科研通管家采纳,获得10
2秒前
学习万岁完成签到 ,获得积分10
5秒前
mengmenglv完成签到 ,获得积分0
6秒前
9秒前
甜蜜的紫菜完成签到,获得积分10
17秒前
顺利毕业完成签到 ,获得积分10
20秒前
24秒前
ADChem_JH完成签到,获得积分10
30秒前
33秒前
aRuuuu完成签到 ,获得积分10
34秒前
35秒前
玩命的芸遥完成签到,获得积分10
36秒前
39秒前
zaq123456完成签到 ,获得积分10
39秒前
40秒前
yyyyy发布了新的文献求助10
47秒前
mianmian186发布了新的文献求助10
48秒前
乐正怡完成签到 ,获得积分0
51秒前
1分钟前
xiaoyi完成签到 ,获得积分10
1分钟前
小红帽完成签到 ,获得积分10
1分钟前
侯子完成签到 ,获得积分10
1分钟前
1分钟前
科目三的应助被Wang采纳,获得10
1分钟前
故意的冷安完成签到,获得积分10
1分钟前
mianmian186发布了新的文献求助30
1分钟前
lucinda完成签到 ,获得积分10
1分钟前
lishuhua完成签到 ,获得积分10
1分钟前
1分钟前
仁爱觅风完成签到 ,获得积分10
1分钟前
科研通AI6.3的应助被mianmian186采纳,获得10
2分钟前
小二郎的应助被科研通管家采纳,获得10
2分钟前
xiaolizi的应助被科研通管家采纳,获得40
2分钟前
yangsheng完成签到 ,获得积分10
2分钟前
阳光灭绝完成签到,获得积分10
2分钟前
jiuzhijiu完成签到,获得积分10
2分钟前
Jasper的应助被微山采纳,获得10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190320
求助须知:如何正确求助?哪些是违规求助? 9577417
关于积分的说明 21852481
捐赠科研通 7788909
什么是DOI,文献DOI怎么找? 3436315
关于科研通互助平台的介绍 2560144
邀请新用户注册赠送积分活动 2482975